{
    "title": "Individual feed for http://feeds.benzinga.com/benzinga",
    "link": "http://feeds.benzinga.com/benzinga",
    "description": "Individual feed output.",
    "lastBuildDate": "2025-12-23T11:01:13.274397",
    "items": [
        {
            "title": "FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug",
            "link": "https://www.benzinga.com/news/health-care/25/12/49560864/fda-asks-reviva-pharmaceuticals-to-conduct-additional-phase-3-study-for-its-schizophrenia-drug",
            "description": "Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a pre-NDA meeting. read more",
            "pubDate": "2025-12-23T14:26:44",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/12/23/An-Elderly-Person-With-Highlighted-Brain.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Cyngn Enters Agriculture With Chandler Automation Alliance",
            "link": "https://www.benzinga.com/markets/tech/25/12/49560685/cyngn-enters-agriculture-with-chandler-automation-alliance",
            "description": "Cyngn added Chandler Automation as a dealer to sell its DriveMod Tugger for automated material movement in food processing. read more",
            "pubDate": "2025-12-23T14:25:53",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/12/23/Cyngn-Inc.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Bitcoin, Ethereum, XRP Have Hit 'Final Low', Raoul Pal Says: 'Do Nothing' To 'Make It' In Bullish 2026",
            "link": "https://www.benzinga.com/crypto/cryptocurrency/25/12/49560593/bitcoin-ethereum-xrp-have-hit-final-low-raoul-pal-says-do-nothing-to-make-it-in-bullish-202",
            "description": "Real Vision CEO Raoul Pal says the crypto market has likely hit its “final low” and urges investors to “do nothing” but hold as a massive wave of glob...",
            "pubDate": "2025-12-23T14:20:16",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/12/23/Bitcoin_2.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Cassava Closes Chapter On Investor Lawsuit With Around $31 Million Deal",
            "link": "https://www.benzinga.com/news/health-care/25/12/49560591/cassava-closes-chapter-on-investor-lawsuit-with-around-31-million-deal",
            "description": "Cassava Sciences agreed to pay $31.25 million to settle a securities class action tied to investors from 2020 to 2023, with no admission of wrongdoing...",
            "pubDate": "2025-12-23T14:20:12",
            "image_url": "https://cdn.benzinga.com/files/images/story/2025/12/23/Legal-Basis-of-the-Ban-Rejected.jpeg?optimize=medium&dpr=1&auto=webp&height=675&width=1200&fit=crop"
        },
        {
            "title": "Here's How Much $1000 Invested In Alcoa 5 Years Ago Would Be Worth Today",
            "link": "https://www.benzinga.com/insights/news/25/12/49560524/heres-how-much-1000-invested-in-alcoa-5-years-ago-would-be-worth-today",
            "description": "read more",
            "pubDate": "2025-12-23T14:15:47",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png"
        }
    ]
}